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Alzheimer’s disease (AD), which is characterized by a degeneration of neurons and their synapses, is one of the most common
forms of dementia. CSF levels of amyloid β42 (Aβ42) have been recognized as a strong candidate to serve as an AD biomarker.
Thereare a number ofcommercial assays thatare routinely employed formeasuring Aβ42;however, these assays give diverse ranges
for the absolute levels of CSF Aβ42. In order to employ CSF Aβ42 as a biomarker across multiple laboratories, studies need to be
performed to understand the relationship between the diﬀerent platforms. We have analyzed CSF samples from both diseased and
nondiseased subjects with two diﬀerent widely used assay platforms. The results showed that diﬀerent values for the levels of CSF
Aβ42 were reported, depending on the assay used. Nonetheless, both assays clearly demonstrated statistically signiﬁcant diﬀerences
in the levels of Aβ42 in CSF from AD relative to age-matched controls (AMC). This paper provides essential data for establishing
the relationship between these assays and provides an important step towards the validation of Aβ42 as a biomarker for AD.
1.Introduction
Alzheimer’s disease (AD) is the most common neurodegen-
erativedisorder.Becausethediseaseisoftendiﬃculttodetect
and diagnose at an early stage, a tremendous need exists for
the identiﬁcation and characterization of biomarkers that
can be used to diagnose early-stage AD, or for monitoring
new therapies for AD in clinical trials. Much interest has
been generated regarding the use of CSF Aβ42 as a biomarker
for diagnosing and tracking AD progression [1, 2]. Several
diﬀerent commercially available assays for measuring Aβ42
are currently employed across laboratories. These assays give
diverse values for the levels of CSF Aβ42 [3, 4]. The relation-
ships between the reported CSF Aβ42 values from these dif-
ferent assays are unclear, but researchers agree in the impor-
tance of standardizing assays for CSF Aβ42 [4].
Schoonenboom et al. compared the Aβ42 CSF measure-
ments from two widely used Aβ42 ELISA assays using the
same CSF sample. Our data extends their ﬁndings by directly
comparing human CSF samples from both diseased and
non diseased subjects with two diﬀerent widely-used assay
platforms, one of which uses colorimetric detection, while
the other employs electrochemiluminescence (ECL) detec-
tion. Comparisons were made to determine if the assays gave
similar values and were able to distinguish CSF from Alzhei-
mer’s subjects or age-matched controls based.
2.MaterialsandMethods
2.1.Subjects. Humancerebrospinalﬂuid(CSF)sampleswere
purchased from Precision Med, Inc. (San Diego, CA), which
is in compliance with all applicable rules and regulations for
human sample collection and dissemination. CSF samples
from 23 individuals with AD (14 males, 9 females, average
age78,averageMMSEscore17)and22age-matchedcontrols
(11 males, 11 females, average age 77) were tested. To avoid
any eﬀects from multiple freeze-thaw cycles, 60μL aliquots
of each CSF sample were placed in randomly assigned wells
in a lo-bind polypropylene tray (Micronic North America,
McMurray, PA). CSF was stored at −80◦C until analysis.2 International Journal of Alzheimer’s Disease
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Figure 1: (a) CSF Aβ42 levels measured in both ELISA and ECL assay. Box plots of CSF Aβ42 levels from ELISA and ECL separated by
diagnosis (AD and AMC) and method of detection. Boxes represent the interquartile ranges: bottom of box, black dot, and top of box
indicate the 25, 50, and 75th percentile of the data. The whiskers (dashed bars) extend to the most extreme data points, which are no more
than1.5timestheheightoftheboxawayfromthetoporbottomofthebox.(b)CorrelationbetweenELISAandECL.Correlationcoeﬃcients
r = 0.819.
All samples were assayed in duplicate in both Aβ42 assays,
conducted by the same experienced scientist.
2.2. CSF Analysis. Innotest β-Amyloid1−42 (Innogenetics,
Alpharetta, GA) is a solid-phase ELISA for measuring the
levels in human CSF utilizing colorimetric detection with
peroxidase-labeled streptavidin. The ELISA was performed
as outlined by the manufacturer’s instructions. Absorbance
at 450nm was measured on the SpectraMax M2 (Molecular
Devices, Sunnyvale, CA), and analysis was preformed using
Softmax 5.2 software. The limit of detection (LOD) of
50pg/mL was calculated by the manufacture as the mean of
8 determinations of the sample diluent.
MSD 96-well MULTI-ARRAY Human (6E10) Aβx−42
assay (MesoScale Discovery, Gaithersburg, MD) was pre-
formed as outlined by the manufacturer’s instructions.
Analysis was performed using MSD workbench version
3.0.17.3 (MSD, Gaithersburg, MD). An LOD of approxi-
mately 20pg/mL was calculated by the manufacture based
on data obtained from 4 diﬀerent product lots (Table 1).
All calibrators were prepared in siliconized polypropylene
tubes (Sigma-Aldrich, St. Louis, MO), and CSF samples were
diluted in 96-well u-bottom polypropylene plates (Costar,
Lowell, MA).
2.3. Statistical Analysis. All statistical analyses and graphics
were performed using either SAS JMP version 8 or R version
2.9.0. A P value < 0.05 was taken to indicate statistical
signiﬁcance. Statistical testing for diﬀerences in mean Aβ42
Table 1
ELISA EC Ratio
pg/mL pg/mL ECL/ELISA
AD (n = 23)
Mean ± SE 500.4 ±44.6 1235.8 ±165.72 . 5
AMC (n = 22)
Mean ± SE 848.3 ±51.9 2280.5 ±184.62 . 7
LOD 50pg/mL 10–20pg/mL
Average 2.6
level among the two diagnosis groups (AD and AMC) was
made using a two-sided, two-sample t-test.
3. Results
The Aβ1−42 ELISA standard curve showed a dynamic range
of 125 to 2000pg/mL, with an LOD of 50pg/mL, and
the average CV based on sample duplicates was 3.9%.
The Aβx−42 ECL assay standard curve showed a dynamic
range of 12 to 3000pg/mL, with an LOD of approximately
20pg/mL, and the average CV based on sample duplicates
was 7.1% (data not shown). The Aβ42 levels in the 45 CSF
samples determined by ELISA and ECL assay are shown in
Figure 1(a).TheAβ42 levelsofalltheCSFsampleswereabove
LODs in both assays. The means of Aβ1−42 measured by
ELISAweresigniﬁcantlylowerinADpatientscomparedwith
AMC (500.4 versus 848.3pg/mL, resp.), (P<0.0001
∗). The
averageCVbasedonsampleduplicateswas6%.MeanAβx−42International Journal of Alzheimer’s Disease 3
measured by ECL assay were also signiﬁcantly lower in AD
patients compared with AMC (1235.8 versus 2280.5pg/mL,
resp.)(P<0.0001
∗).TheaverageCVbasedonsampledupli-
cates was 8.4%. Although absolute concentrations varied
between the ELISA and ECL, the correlation coeﬃcient for
CSF Aβ42 was r = 0.819 and highly signiﬁcant (P<0.0001)
(Figure 1(b)).
4. Discussion
Weprovidehereadirectcomparisonbetweentwocommonly
used assays, ELISA and ECL assay, in measuring Aβ42 levels
in human CSF. Both the ELISA and ECL assay showed that
Aβ42 washigherintheAMCthantheADgroup.Theseobser-
vations in subject diﬀerentiation are similar to other pub-
lished reports [1, 4–6].
We observed that in general Aβ42 levels were 2.6-fold
higher in the ECL assay relative to the ELISA. The observed
diﬀerences may be related to a number of factors including
the matrix (i.e., diﬀerent assay dilution buﬀers and reage-
nts), the purity of the calibrators, and diﬀerences in the aﬃ-
nityofthecaptureanddetectionantibodies[3,7].TheELISA
assay uses monoclonal antibody 21F12 as the capture anti-
body,whichrecognizesAβ1−42.Incontrast,ECLassayusesan
undisclosed antibody, which recognizes Aβx−42 as the captu-
re antibody. There is also a lack of synchronization between
the two assays due to the diﬀerence between the two calibra-
tors. We conducted an experiment swapping the calibrators
between the two kits. Both assays detected the other kits’
calibrator; however, the % recovery was not at an acceptable
level (data not shown).
Although both are plate-based methods, the detection
technologies for measuring the CSF Aβ42 concentrations are
diﬀerent and could be a contributing factor to the underly-
ing diﬀerence. The ELISA signal is detected with a peroxida-
se-labeled streptavidin antibody and the result is colorimet-
ric, which provides the desired sensitivity but less dynamic
range.TheECLsignalisdetectedbyincorporatingaSULFO-
TAG labeled antibody that emits light upon electrochemical
stimulation initiated at the electrode, which provides sensi-
tivity similar to the ELISA but a broader dynamic range.
5. Conclusion
Currently, quality control eﬀorts are under investigation to
evaluate interlaboratory variance components and to aid in
the standardization of CSF Aβ42 measurements [1]. In addi-
tion, larger harmonization studies are needed that include
the assays studied here as well as other manufactures assays
for the measurement of Aβ42 in human CSF. The present
study provides an important ﬁrst step by comparing and
establishing the relationship between two widely used plat-
forms for measuring Aβ42.
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